^
    Back
    Association details:
    Biomarker:PGR positive
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2022
    Title:

    Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial

    Published date:
    05/26/2022
    Excerpt:
    The Short-HER study randomized 1254 patients with HER2+ early breast cancer to receive 9 weeks vs 1 year of adjuvant trastuzumab combined with anthracycline-taxane chemotherapy. 853 patients with HR+ BC (ER and/or PgR >10%) were included…patients who received AI had a significantly better DFS as compared to patients who received TAM or TAM-AI: 7-yr DFS 87.3% vs 81.7%, log-rank P=0.017 (HR 1.46, 95%CI 1.05-2.03).
    Secondary therapy:
    Aromatase inhibitor; Chemotherapy
    DOI:
    10.1200/JCO.2022.40.16_suppl.547
    Trial ID:
    ShortHER
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

    Excerpt:
    ......
    Trial ID:
    NCT00134680
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

    Excerpt:
    ...- Estrogen receptor-positive and/or progesterone receptor-positive disease...
    Trial ID:
    ShortHER
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer

    Excerpt:
    ...- Estrogen receptor or progesterone receptor positive...
    Trial ID:
    NCT00053339
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Neo- / adjuvant trial to compare two therapies for patients with high rist breast cancer. Patients will receive either dose-dense the combination EnPC or dose-dense and dose-tailored EC-D (GAIN-2). Neo- / adjuvante Studie zum Vergleich zweier Therapiearme bei Brustkrebs-Patientinnen mit erhöhtem Risiko. Patientinnen erhalten entweder dosisdicht die Kombination EnPC oder dosisdicht und dosisangepasst EC-D.

    Excerpt:
    ...High risk breast cancer as defined as: • HER2 positive or triple-negative tumors irrespective of nodal status or • Luminal B-like tumors (ER and/or PgR positive, HER2 negative, Ki-67 > 20%) with involved lymph nodes or • 4 or more involved lymph nodes. ...
    Trial ID:
    2011-005214-11
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

    Excerpt:
    ...- Estrogen receptor- and/or progesterone receptor-positive tumor...
    Trial ID:
    SAKK 23/03
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer

    Excerpt:
    ...- Estrogen receptor- and/or progesterone receptor-positive or negative tumor...
    Trial ID:
    NCT00450892
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

    Excerpt:
    ...- Estrogen receptor and/or progesterone receptor positive...
    Trial ID:
    NCT00057993